Psychiatric NP Scope of Practice for Narcolepsy in North Carolina

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients remotely, you’re navigating one of the most complex regulatory landscapes in telemedicine. Narcolepsy requires stimulants and other controlled substances — medications that trigger a web of federal DEA rules, state prescribing laws, and scope-of-practice restrictions that vary wildly depending on where you practice and what license you hold.

Here’s the reality: As of 2026, you can prescribe narcolepsy medications via telehealth in most states — but only because of temporary federal waivers that expire December 31, 2026. After that? The rules could tighten significantly, potentially requiring in-person exams before you can prescribe Schedule II stimulants like Adderall or methylphenidate.

This guide breaks down exactly what you need to know right now: the current DEA telehealth flexibilities, how psychiatrist vs PMHNP scope differs for narcolepsy care, and the critical state-by-state variations that determine whether you can actually treat these patients remotely — or need workarounds.

The Federal Foundation: DEA Rules for Telehealth Prescribing of Controlled Substances

The Ryan Haight Act (2008) is still the law — and it normally prohibits prescribing any controlled substance via telemedicine without at least one in-person medical evaluation (21 U.S.C. §829(e)). That means before COVID, if you wanted to prescribe Adderall or modafinil to a narcolepsy patient, you needed to see them in person at least once, or fit into one of several narrow exceptions (like treating a patient in a DEA-registered facility or covering for another provider who saw them in person).

Then COVID hit. In March 2020, the DEA waived that in-person requirement entirely under public health emergency authority. Suddenly, providers could prescribe Schedule II–V medications via telehealth without ever meeting the patient face-to-face, as long as the prescription was legitimate and all other requirements were met (state licensure, DEA registration, standard of care, etc.).

That emergency waiver was supposed to end when the Public Health Emergency ended in May 2023. But the DEA, recognizing the chaos that would cause, kept extending it. First through late 2023, then through 2024, and most recently through December 31, 2026 (HHS Press Release, Jan 2026).

What this means for you today: You can initiate narcolepsy treatment via telehealth and prescribe stimulants, modafinil, sodium oxybate, and other controlled medications without requiring an in-person visit — but only until the end of 2026. After that, the rules depend on what permanent DEA regulations look like, which are still being finalized.

What’s Coming: Permanent DEA Telehealth Rules

The DEA has been working on permanent telemedicine prescribing rules since 2022. Early proposals suggested requiring an in-person exam after an initial 30-day telehealth prescription, and potentially banning telehealth initiation of Schedule II stimulants altogether. Those proposals got torpedoed — over 38,000 public comments pushed back hard, and the DEA shelved them (DEA Press Release, Nov 2024).

Instead, the DEA has issued only two narrow final rules so far (both in January 2025): one expanding telehealth prescribing of buprenorphine for opioid use disorder, and another allowing VA patients to continue controlled substance care via telemedicine (DEA Press Release, Dec 2025). These suggest the DEA is willing to carve out condition-specific exceptions.

For narcolepsy, no special exception exists yet. Expect permanent rules sometime in 2025–2026 that will likely impose some restrictions — maybe an initial 30-day supply limit with required follow-up, or mandating an in-person exam within a certain timeframe. Plan accordingly.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist vs PMHNP Scope for Narcolepsy: Who Can Prescribe What?

Psychiatrists (MD/DO): Full Authority (With State Nuances)

If you’re a psychiatrist, you have the broadest authority to treat narcolepsy. You can diagnose it, order sleep studies, and prescribe any Schedule II–V medication needed — assuming you have:

• A valid medical license in the state where the patient is located
• A DEA registration with Schedule II authority
• Compliance with state-specific prescribing rules (PDMP checks, e-prescribing mandates, etc.)

There’s no law preventing psychiatrists from treating narcolepsy, even though it’s technically a sleep disorder often managed by neurologists. You’re diagnosing and managing a condition that overlaps heavily with psychiatric medication expertise (stimulants for ADHD, antidepressants for cataplexy, etc.).

One state-specific wrinkle: Some states explicitly list narcolepsy as an approved indication for Schedule II stimulants. For example, Florida statute lists narcolepsy, ADHD, drug-induced brain dysfunction, epilepsy, and refractory depression as the only lawful uses for prescribing Schedule II amphetamines (Fla. Stat. §464.012). Narcolepsy is on that list — so you’re affirmatively permitted to prescribe stimulants for it. But prescribing them for an off-label use not on that list could trigger scrutiny.

PMHNPs: Authority Depends Heavily on State

If you’re a Psychiatric Mental Health Nurse Practitioner, your ability to treat narcolepsy — and especially to prescribe the controlled medications it requires — varies wildly by state.

Full Practice Authority States (California, New York, Illinois):

• California: As of 2023, experienced NPs (≥4,600 hours of supervised practice) can obtain full practice authority and prescribe Schedule II–V medications independently (RxAgent, Dec 2025). You need to complete specific controlled substance pharmacology training and obtain a DEA registration with Schedule II authority (CA BRN). Once you have that, you can diagnose narcolepsy and prescribe stimulants or modafinil without a supervising physician.

• New York: Experienced NPs (>3,600 hours) practice independently with full prescriptive authority for Schedule II–V meds (Rivkin Rounds, Apr 2022). You can treat narcolepsy entirely on your own — diagnose, coordinate sleep studies, prescribe controlled meds. New York recently aligned its telehealth controlled substance rules with federal law (Nixon Peabody, June 2025), so as long as DEA waivers are in effect, you can prescribe via telehealth without an in-person visit.

• Illinois: NPs can achieve full practice authority after 4,000 hours of collaborative practice plus 250 hours of continuing education (RxAgent, Dec 2025). You need a state mid-level controlled substance license, but once you have FPA, you can prescribe Schedule II stimulants for narcolepsy independently. (Illinois does require a ‘consultation relationship’ with a physician if prescribing benzodiazepines or opioids — but stimulants aren’t opioids, so that doesn’t apply here.)

Reduced/Restricted Practice States (Pennsylvania, Florida, Texas):

• Pennsylvania: CRNPs need a collaborative agreement with a physician and can only prescribe Schedule II meds in 30-day supply increments with physician oversight (PA Code & Bulletin, 2021–2022). For ongoing narcolepsy care requiring long-term stimulants, you’ll need periodic physician consultation. Schedule III–IV meds have a 90-day limit. You can manage narcolepsy, but you’re working under a physician agreement.

• Florida: This is tricky. Florida NPs can prescribe controlled substances, but Schedule II prescriptions are limited to 7 days — unless you’re a ‘psychiatric nurse’ (PMHNP with specific training/experience) prescribing for a mental health disorder (Fla. Stat. §464.012). Narcolepsy is not a mental health disorder — it’s a neurological sleep disorder. So even if you’re a psychiatric NP, the 7-day cap applies for narcolepsy stimulants. In practice, you might start a patient on a short supply, but long-term management will require physician involvement. Many Florida NPs use modafinil (Schedule IV) instead, which has fewer restrictions.

• Texas: APRNs cannot prescribe Schedule II controlled substances in outpatient settings at all — period (Texas Medical Board FAQ). The only exceptions are inpatient hospital admissions or hospice care. So if you’re a PMHNP in Texas, you cannot prescribe Adderall or methylphenidate for a narcolepsy patient outside a hospital. You’d need a supervising physician to write those prescriptions. You can prescribe Schedule III–V meds (like modafinil) under delegation.

Bottom line for PMHNPs: In full-practice states, you can run a narcolepsy telehealth practice independently. In restricted states, you need physician backup — either for collaboration, delegation, or to handle Schedule II prescriptions directly.

State-by-State Telehealth Prescribing Rules for Narcolepsy

Beyond scope of practice, each state has its own telehealth prescribing rules — especially for controlled substances. Here’s how the six key states stack up:

California

• Telehealth allowed? Yes, with no state-imposed in-person requirement for controlled substances.
• Special rules: None beyond federal law. You must check the CURES PDMP before prescribing Schedule II–IV meds and use e-prescribing.
• Narcolepsy-specific: No restrictions. Psychiatrists and independent NPs can prescribe stimulants via telehealth under current DEA waivers.

Texas

• Telehealth allowed? Yes, but requires two-way audio-visual communication (video required, not just phone) for controlled substances (CCHP, Fall 2025).
• Special rules: Texas bans telehealth prescribing of controlled substances for chronic pain management (opioids), but narcolepsy isn’t chronic pain, so that doesn’t apply.
• Narcolepsy-specific: APRNs can’t prescribe Schedule II remotely (or at all in outpatient settings), so telehealth narcolepsy care requires an MD/DO.

Florida

• Telehealth allowed? Not for Schedule II stimulants used for narcolepsy. Florida law prohibits prescribing Schedule II or III controlled substances via telehealth except for psychiatric disorders, inpatient care, hospice, or nursing home patients (Fla. Stat. §456.47). Since narcolepsy is neurological (not psychiatric), you cannot prescribe Adderall or other Schedule II stimulants via telehealth in Florida — even as a psychiatrist.
• Workaround: Use modafinil (Schedule IV, allowed via telehealth) or require at least one in-person visit to prescribe stimulants.
• Narcolepsy-specific: This is the most restrictive state for telehealth narcolepsy care.

New York

• Telehealth allowed? Yes, as long as you comply with federal law. New York’s 2025 rule requires an in-person exam before prescribing controlled substances unless you meet an exception — and one exception is that you’re following DEA telemedicine rules (Nixon Peabody, June 2025).
• Special rules: Must check I-STOP PDMP before each controlled substance prescription. E-prescribing mandatory.
• Narcolepsy-specific: Currently wide open for telehealth under DEA waivers. If DEA tightens rules in 2027, New York’s in-person requirement will kick back in unless you use one of the state’s other exceptions (e.g., covering provider, recent referral from another provider who examined the patient).

Pennsylvania

• Telehealth allowed? Yes, with no specific state ban on controlled substances via telehealth. Pennsylvania defers to federal DEA rules.
• Special rules: NPs can only prescribe 30-day supplies of Schedule II meds (with physician consultation for continuation). Must check PA PDMP.
• Narcolepsy-specific: Straightforward for MDs; CRNPs need collaborative agreement and physician oversight for long-term stimulant management.

Illinois

• Telehealth allowed? Yes. Illinois has no state-level restriction on controlled substance telehealth prescribing beyond federal law.
• Special rules: E-prescribing mandatory for controlled substances (as of Jan 2023). Must check Illinois PMP.
• Narcolepsy-specific: Full-practice NPs can handle this independently. Less-experienced NPs need physician collaboration with delegation for Schedule II authority.

The Economics of Telehealth Narcolepsy Care

One reason to consider joining a platform like Klarity Health for narcolepsy care: patient acquisition is expensive and time-consuming when you go solo.

If you’re doing DIY marketing to attract narcolepsy patients:

• SEO takes 6–12 months of consistent investment before generating meaningful patient flow. You need expertise in healthcare SEO, content creation, technical optimization — or you’re hiring an agency at $2,000–5,000/month.
• Google Ads for mental health and sleep disorder keywords run $15–40+ per click. Most clicks don’t convert to booked patients. Realistically, you’re spending $200–500+ per booked patient once you factor in ad spend, testing, failed campaigns, and no-shows from cold leads.
• Directory listings (Psychology Today, Zocdoc, etc.) charge monthly fees and you’re competing with hundreds of other providers. Zocdoc charges $35–100+ per booking, plus subscription costs.

Total reality: Acquiring a qualified psychiatric patient through DIY channels costs $200–500+ when you factor in all costs — agency fees, ad spend, staff time to handle leads, no-show rates, months of wasted SEO investment, failed campaigns.

Klarity’s model is different: You pay a standard listing fee per new patient lead (similar to Zocdoc’s pay-per-appointment model). No upfront marketing spend. No monthly subscriptions. Pre-qualified patients already matched to your specialty and availability. Built-in telehealth infrastructure. Both insurance and cash-pay patient flow. You control your schedule — and you only pay when you see patients.

Frame it this way: Instead of gambling $3,000–5,000/month on marketing with uncertain results, you pay only when a qualified narcolepsy patient books with you. That’s guaranteed ROI vs. throwing money at marketing channels that may never convert.

Practical Steps for Providers Treating Narcolepsy via Telehealth

1. Verify your state’s rules. If you’re in Florida, you need a workaround for Schedule II prescribing (in-person visit or use modafinil). If you’re in Texas as an NP, you need physician backup.

2. Get multi-state licensed. Narcolepsy is rare — patients often can’t find local specialists. Join the Interstate Medical Licensure Compact (IMLC) if eligible (covers IL, TX, PA, but not NY, FL, CA) to expand your reach.

3. Set up PDMP access in every state you practice. California (CURES), New York (I-STOP), Texas PMP, Illinois PMP, Pennsylvania PDMP, Florida E-FORCSE — you’re legally required to check these before prescribing controlled substances. Most EHR/e-prescribing platforms integrate PDMP lookups.

4. Use e-prescribing for all controlled substances. It’s mandatory in most states (CA, NY, IL as of 2023). Paper prescriptions for Schedule II meds are largely banned.

5. Coordinate sleep study access. Confirming narcolepsy typically requires polysomnography and Multiple Sleep Latency Testing. Build referral relationships with local sleep labs in the states where your patients are located — or partner with a platform that handles this coordination.

6. Document thoroughly. For controlled substance prescribing via telehealth, your clinical justification needs to be airtight. Use rating scales (Epworth Sleepiness Scale), document objective findings on video (patient alertness, cognitive function), and clearly note the medical necessity for stimulants or other meds.

7. Plan for post-2026 DEA rules. When permanent regulations hit, you may need to add in-person visits or hybrid care models. Start thinking now about how you’d structure that.

FAQs: Prescribing Narcolepsy Medications via Telehealth

Can I prescribe Adderall via telehealth for narcolepsy in 2026?
Yes — if you’re practicing in a state that allows it and you meet DEA requirements. Currently, the DEA’s temporary waiver (through Dec 31, 2026) permits prescribing Schedule II stimulants via telehealth without an in-person exam. Exception: Florida law prohibits Schedule II telehealth prescribing for non-psychiatric conditions, so Adderall for narcolepsy is not allowed remotely in FL unless you do at least one in-person visit.

Do PMHNPs have the same authority as psychiatrists to prescribe narcolepsy meds?
It depends on the state. In full-practice states (CA, NY, IL), experienced PMHNPs can prescribe Schedule II stimulants independently. In restricted states (TX, FL, PA), NPs need physician collaboration or cannot prescribe Schedule II at all (Texas). Scope varies widely.

What happens when the DEA telehealth waivers expire in December 2026?
The DEA is expected to finalize permanent telemedicine prescribing rules before then. Likely outcomes: an initial 30-day telehealth prescription allowed with required follow-up, or mandating an in-person exam within a certain timeframe. Until final rules are published, plan for potential tightening of telehealth controlled substance prescribing after 2026.

Can I use audio-only (phone) visits to prescribe narcolepsy medications?
Not in most states. Texas explicitly requires two-way audio-visual (video) for prescribing controlled substances. California, New York, Illinois, Pennsylvania, and Florida generally expect video for initial evaluations and controlled substance prescribing to meet standard of care, though some states allow audio-only for follow-ups in mental health care.

Do I need to check the state PDMP every time I prescribe a stimulant?
Yes. California requires PDMP checks before initial Schedule II–IV prescriptions and at least every 4 months if continuing. New York requires checking I-STOP before each controlled substance prescription. Texas, Illinois, Pennsylvania, and Florida have similar mandates. This is non-negotiable — failing to check can result in state board discipline.

Can I prescribe modafinil (Schedule IV) more easily than Adderall (Schedule II) via telehealth?
Generally, yes. Modafinil faces fewer state restrictions than Schedule II stimulants. For example, Florida allows Schedule IV prescribing via telehealth without the carve-outs required for Schedule II. If you’re practicing in a restricted state, modafinil or armodafinil may be your go-to first-line medication for telehealth narcolepsy care.

What about sodium oxybate (Xyrem) for narcolepsy with cataplexy?
Sodium oxybate is Schedule III with an FDA-mandated REMS program — you must be enrolled in the REMS to prescribe it. It’s allowed via telehealth under current DEA waivers, but involves extra administrative steps (restricted distribution, patient education, enrollment). Most telehealth providers refer complex narcolepsy-with-cataplexy cases requiring Xyrem to in-person specialists unless they’re willing to handle the REMS overhead.

Why Join Klarity Health for Narcolepsy Telehealth?

If you’re a psychiatrist or PMHNP looking to expand into narcolepsy care (or already treating it and want more patients), Klarity offers a turnkey solution that removes the risk and overhead of DIY patient acquisition:

• No upfront marketing spend or monthly fees — you pay a standard listing fee only when a qualified patient books with you
• Pre-qualified, matched patients — no wasted time on leads that don’t convert or no-shows from cold advertising
• Built-in telehealth infrastructure — HIPAA-compliant video platform, e-prescribing integration, PDMP access tools
• Both insurance and cash-pay patient flow — diversify your revenue streams
• You control your schedule — set your availability, see patients when it works for you

Instead of spending thousands per month gambling on Google Ads or waiting months for SEO to maybe pay off, you get guaranteed ROI: pay when you see patients, not before.

Ready to expand your practice? Join Klarity Health’s provider network and start treating narcolepsy patients across multiple states — without the headache of figuring out patient acquisition yourself.

Join Klarity’s Provider Network →

Sources and References

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (Jan 2, 2026) – www.hhs.gov

2. DEA Press Release – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (Nov 15, 2024) – www.dea.gov

3. 21 U.S.C. §829(e) Ryan Haight Act (Federal Law defining in-person medical evaluation requirement for controlled substance prescribing) – www.law.cornell.edu

4. Florida Statute §456.47 – Use of Telehealth to Provide Services (telehealth prescribing restrictions for Schedule II/III controlled substances) – www.leg.state.fl.us

5. Nixon Peabody Legal Alert – ‘New York State Finalizes Telemedicine Rule for Controlled Substances’ (June 18, 2025) – www.nixonpeabody.com

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206